PMID- 35096555
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Safety and Efficacy of Transarterial Chemoembolization Combined With Immune 
      Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular 
      Carcinoma.
PG  - 657512
LID - 10.3389/fonc.2021.657512 [doi]
LID - 657512
AB  - PURPOSE: To explore the safety and efficacy of transarterial chemoembolization 
      (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine 
      kinase inhibitors (TKIs) for the treatment of unresectable hepatocellular 
      carcinoma (uHCC). MATERIALS AND METHODS: From August 2019 to July 2020, patients 
      who received TACE combined with ICIs and TKIs were retrospectively analyzed. 
      Treatment-related adverse events (AEs) were recorded. The Kaplan-Meier method was 
      used to estimate time to progression (TTP) and progression-free survival (PFS). 
      RESULTS: In total, 31 patients with uHCC were included. Eleven patients were 
      classified as BCLC-C. Nineteen patients had multiple lesions, and the cumulative 
      targeted lesions were 69 mm (range, 21-170 mm) according to mRECIST. Twenty-nine 
      (93%) patients experienced at least one AE during the treatment. Four (12.9%) 
      patients developed AEs of higher grade (grade>/=3). The objective response rate 
      (ORR) and disease control rate (DCR) were 64.5% and 77.4%, respectively. The 
      median time to response was 7 weeks (range, 4-30 w), and the duration of response 
      was 17.5 weeks (range, 2-46 w). From the first ICIs, TTP and PFS were 6.5 months 
      (95% CI, 3.5-11) and 8.5 months (95% CI, 3.5-NE), respectively. CONCLUSIONS: TACE 
      combined with ICIs and TKIs shows an acceptable safety profile and considerable 
      efficacy in patients with HCC.
CI  - Copyright (c) 2022 Yang, Yang, Xiang, Zhong, Li, Shen, Zhang, Yin, Sun, Wang and 
      Zhu.
FAU - Yang, Fei
AU  - Yang F
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
AD  - Department of Interventional Radiology, Affiliated Hospital of Jiangnan 
      University, Wuxi, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Xiang, Wei
AU  - Xiang W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
AD  - Department of Oncology Intervention, Taizhou Municipal Hospital, Taizhou, China.
FAU - Zhong, Bin-Yan
AU  - Zhong BY
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Li, Wan-Ci
AU  - Li WC
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Shen, Jian
AU  - Shen J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Zhang, Shuai
AU  - Zhang S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Yin, Yu
AU  - Yin Y
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Sun, Hong-Peng
AU  - Sun HP
AD  - Department of Child Health, Jiangsu Key Laboratory of Preventive and 
      Translational Medicine for Geriatric Diseases, School of Public Health, Soochow 
      University, Suzhou, China.
FAU - Wang, Wan-Sheng
AU  - Wang WS
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Zhu, Xiao-Li
AU  - Zhu XL
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220113
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8792047
OTO - NOTNLM
OT  - TACE
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - targeted therapy
OT  - tyrosine kinase inhibitors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2021/01/01
CRDT- 2022/01/31 05:59
PHST- 2021/01/23 00:00 [received]
PHST- 2021/12/20 00:00 [accepted]
PHST- 2022/01/31 05:59 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.657512 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jan 13;11:657512. doi: 10.3389/fonc.2021.657512. eCollection 
      2021.